Cytology and Genetics

, 42:120 | Cite as

Application of multiplex PCR with histopathologic features for detection of familial breast cancer in formalin-fixed, paraffin-embedded histological specimens

  • H. Rassi
  • N. G. Gorovenko
  • M. Houshmand
  • S. V. Podolskaya
  • M. Hashemi
  • K. Majidzadeh
  • M. H. Hosseini Akbari
  • M. Shafa Shariat Panahi
Article

Abstract

Breast cancer is the most common malignancy among females in the world. In Iran, age and family history are the major risk factors for the development of this disease. Mutations of BRCA1 and BRCA2 genes are associated with a greatly increased risk for familial breast cancer. The frequency of BRCA mutations was identified in familial breast cancers (FBCs) and nonfamilial breast cancers (NFBCs) by molecular genetics, and morphological and immunohistochemical methods. Thirty-four formalin-fixed, paraffin-embedded breast tissue tumors were analyzed from 16 patients with FBCs and 18 patients with NFBCs. Three 5382insC mutations were detected by multiplex PCR in 16 FBCs. The immunohistochemical method was used to detect estrogen receptors (ER), progesterona receptors (PR), and TP53. Comparison of ER, PR, and TP53 exhibited a high difference (P < 0.0001) in FBCs and NFBCs. Our results demonstrated that 5382insC mutation, ER, PR, TP53, mitotic activity, polymorphism, necrosis and tubules can serve as the major risk factors for FBC.

References

  1. 1.
    Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P., Global Cancer Statistics 2002, Cancer J. Clin., 2005, vol. 55, no. 2, pp. 74–108.CrossRefGoogle Scholar
  2. 2.
    Montazeri, A., Ebrahimi, M., Mehrdad, N., Ansari, M., and Sajadian, A., Delayed Presentation in Breast Cancer: a Study in Iranian Women, BMC Womens Health, 2003, vol. 3, no. 1, p. 4.PubMedCrossRefGoogle Scholar
  3. 3.
    Harirchi, I., Ebrahimi, M., Zamani, N., Jarvandi, S., and Montazeri, A., Breast Cancer in Iran: a Review of 903 Case records, Publ. Health, 2000, vol. 114, pp. 143–145.CrossRefGoogle Scholar
  4. 4.
    Collaborative Group on Hormonal Factors in Breast Cancer. FBC: Collaborative Reanalysis of Individual Data from 52 Epidemiological Studies Including 58.209 Women with Breast Cancer and 101.986 Women without the Disease, Lancet., 2001, vol. 358, pp. 1389–1399.Google Scholar
  5. 5.
    Ford, D., Easton, D.F., Bishop, D.T., Narod, S.A., and Goldgar, D.E., Risks of Cancer in BRCA1-Mutation Carriers. Breast Cancer Linkage Consortium, Lancet., 1994, vol. 343, pp. 692–695.PubMedCrossRefGoogle Scholar
  6. 6.
    Easton, D.F., Steele, L., Fields, P., Ormiston, W., Averill, D., Daly, P.A., McManus, R., Neuhausen, S.L., Ford, D., Wooster, R., Cannon-Albright, L.A., Stratton, M.R., and Goldgar, D.E., Cancer Risks in Two Large Breast Cancer Families Linked to BRCA2 on Chromosome 13q12–13, Amer. J. Hum. Genet., 1997, vol. 61, pp. 120–128.PubMedCrossRefGoogle Scholar
  7. 7.
    Satagopan, J.M., Offit, K., Foulkes, W., Robson, M.E., Wacholder, S., Eng, C.M., Karp, S.E., and Begg, C.B., The Life-Time Risks of Breast Cancer in Ashkenazi Jewish Carriers of BRCA1 and BRCA2 Mutations, Cancer Epidem. Biomark. Prev., 2001, vol. 10, pp. 467–473.Google Scholar
  8. 8.
    Struewing, J.P., Hartge, P., Wacholder, S., Baker, S.M., Berlin, M., McAdams, M., Timmerman, M.M., Brody, L.C., and Tucker, M.A., The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 Among Ashkenazi Jews, N. Engl. J. Med., 1997, vol. 336, pp. 1401–1408.PubMedCrossRefGoogle Scholar
  9. 9.
    An Open Access On-Line Breast Cancer Mutation Data Base. Bethesda, Md: National Human Genome Research Institute, 2002, Available online, Last accessed September 27, 2004.Google Scholar
  10. 10.
    Fodor, F.H., Weston, A., Bleiweiss, I.J., McCurdy, L.D., Walsh, M.M., Tartter, P.I., Brower, S.T., and Eng, C.M., Frequency and Carrier Risk Associated with Common BRCA1 and BRCA2 Mutations in Ashkenazi Jewish Breast Cancer Patients, Amer. J. Hum. Genet., 1998, vol. 63, no. 1, pp. 45–51.PubMedCrossRefGoogle Scholar
  11. 11.
    Lakhani, S.R., Easton, D.F., and Stratton, M.R., The Breast Cancer Linkage Consortium. Pathology of FBC: Differences between Breast Cancers in Carriers of BRCA1 or BRCA2 Mutations and Sporadic Cases, Lancet., 1997, vol. 349, pp. 1505–1510.CrossRefGoogle Scholar
  12. 12.
    Lakhani, S.R., Jacquemier, J., Sloane, J.P., Gusterson, B.A., Anderson, T.J., van de Vijver, M.J., Farid, L.M., Venter, D., Antoniou, A., Storfer-Isser, A., Smyth, E., Steel, C.M., Haites, N., Scott, R.J., Goldgar, D., Neuhausen, S., Daly, P.A., Ormiston, W., McManus, R., Scherneck, S., Ponder, B.A., Ford, D., Peto, J., Stoppa-Lyonnet, D., Bignon, Y.J., Struewing, J.P., Spurr, N.K., Bishop, D.T., Klijn, J.G., Devilee, P., Cornelisse, C.J., Lasset, C., Lenoir, G., Barkardottir, R.B., Egilsson, V., Hamann, U., Chang-Claude, J., Sobol, H., Weber, B., Stratton, M.R., and Easton, D.F., Multifactorial Analysis of Differences between Sporadic Breast Cancers and Cancers Involving BRCA1 and BRCA2 Mutations, J. Nat. Cancer Inst., 1998, vol. 90, pp. 1138–1145.PubMedCrossRefGoogle Scholar
  13. 13.
    Lakhani, S.R., Gusterson, B.A., Jacquemier, J., Sloane, J.P., Anderson, T.J., van de Vijver, M.J., Venter, D., Freeman, A., Antoniou, A., McGuffog, L., Smyth, E., Steel, C.M., Haites, N., Scott, R.J., Goldgar, D., Neuhausen, S., Daly, P.A., Ormiston, W., McManus, R., Scherneck, S., Ponder, B.A., Futreal, P.A., Peto, J., Stoppa-Lyonnet, D., Bignon, Y.J., and Stratton, M.R., The Pathology of FBC: Histological Features of Cancers in Families Not Attributable to Mutations in BRCA1 or BRCA2, Clin. Cancer Res., 2000, vol. 6, pp. 782–789.PubMedGoogle Scholar
  14. 14.
    Lakhani, S.R., van de Vijver, M.J., Jacquemier, J., Anderson, T.J., Osin, P.P., McGuffog, L., and Easton, D.F., The Pathology of FBC: Predictive Value of Immunohistochemical Markers Estrogen Receptor, Progesterone Receptor, HER-2, and p53 in Patients with Mutations in BRCA1 and BRCA2, J. Clin. Oncol., 2002, vol. 20, pp. 2310–2318.PubMedCrossRefGoogle Scholar
  15. 15.
    Bernstein, J.L., Thompson, W.D., Casey, G., DiCioccio, R.A., Whittemore, A.S., Diep, A.T., Thakore, S.S., Vaziri, S., Xue, S., and Haile, R.W., Comparison of Techniques for the Successful Detection of BRCA1 Mutations in Fixed Paraffin-Embedded Tissue, Cancer Epidemiol. Biomarkers Prev., 2002, vol. 11, no. 9, pp. 809–814.PubMedGoogle Scholar
  16. 16.
    Cooper, M., Li, S.Q., Bhardwaj, T., Rohan, T., and Kandel, R.A., Evaluation of Oligonucleotide Arrays for Sequencing of the p53 Gene in DNA from Formalin-Fixed, Paraffin-Embedded Breast Cancer Specimens, Clin. Chem., 2004, vol. 50, no. 3, pp. 500–508.PubMedCrossRefGoogle Scholar
  17. 17.
    Chan, P.C., Wong, B.Y., Ozcelik, H., and Cole, D.E., Simple and Rapid Detection of BRCA1 and BRCA2 Mutations by Multiplex Mutagenically Separated PCR, Clin. Chem., 1999, vol. 45, no. 8, pp. 1285–1287.PubMedGoogle Scholar
  18. 18.
    Neuhausen, S., Gilewski, T., Norton, L., Tran, T., McGuire, P., Swensen, J., Hampel, H., Borgen, P., Brown, K., Skolnick, M., Shattuck-Eidens, D., Jhanwar, S., Goldgar, D., and Offit, K., Recurrent BRCA2 6174delT Mutations in Ashkenazi Jewish Women Affected by Breast Cancer, Nature Genet., 1996, vol. 13, pp. 126–128.PubMedCrossRefGoogle Scholar
  19. 19.
    Roa, B.B., Boyd, A.A., Volcik, K., and Richards, C.S., Ashkenazi Jewish Population Frequencies for Common Mutations in BRCA1 and BRCA2, Nature Genet., 1996, vol. 14, pp. 185–187.PubMedCrossRefGoogle Scholar
  20. 20.
    Oddoux, C., Struewing, J.P., Clayton, C.M., Neuhausen, S., Brody, L.C., Kaback, M., Haas, B., Norton, L., Borgen, P., Jhanwar, S., Goldgar, D., Ostrer, H., and Offit, K., The Carrier Frequency of the BRCA2 6174delT Mutation among Ashkenazi Jewish Individuals is Approximately 1%, Nature Genet., 1996, vol. 14, pp. 188–190.PubMedCrossRefGoogle Scholar
  21. 21.
    Struewing, J.P., Abeliovich, D., Peretz, T., Avishai, N., Kaback, M.M., Collins, F.S., and Brody, L.C., The Carrier Frequency of the BRCA1 185delAG Mutation is Approximately 1 Percent in Ashkenazi Jewish Individuals, Nature Genet., 1995, vol. 11, pp. 198–200.PubMedCrossRefGoogle Scholar
  22. 22.
    Bar-Sade, R.B., Kruglikova, A., Modan, B., Gak, E., Hirsh-Yechezkel, G., Theodor, L., Novikov, I., Gershoni-Baruch, R., Risel, S., Papa, M.Z., Ben-Baruch, G., and Friedman, E., The 185delAG BRCA1 Mutation Originated Before the Dispersion of Jews in the Diaspora and is Not Limited to Ashkenazim, Hum. Mol. Genet., 1998, vol. 7, no. 5, pp. 801–805.PubMedCrossRefGoogle Scholar
  23. 23.
    Szabo, C.I. and King, M.C., Population Genetics of BRCA1 and BRCA2, Amer. J. Hum. Genet., 1997, vol. 60, pp. 1013–1020.PubMedGoogle Scholar
  24. 24.
    Tereschenko, I.V., Basham, V.M., Ponder, B.A., and Pharoah, P.D., BRCA1 and BRCA2 Mutations in Russian FBC, Hum. Mutat., 2002, vol. 19, no. 2, p. 184.PubMedCrossRefGoogle Scholar
  25. 25.
    Perkowska, M., BroZek, I., Wysocka, B., Haraldsson, K., Sandberg, T., Johansson, U., Sellberg, G., Borg, A., and Limon, J., BRCA1 and BRCA2 Mutation Analysis in Breast-Ovarian Cancer Families from Northeastern Poland, Hum. Mutat., 2003, vol. 21, no. 5, pp. 553–554.PubMedCrossRefGoogle Scholar
  26. 26.
    Simard, J., Tonin, P., Durocher, F., Morgan, K., Rommens, J., Gingras, S., Samson, C., Leblanc, J.F., Belanger, C., Dion, F., et al., Common Origins of BRCA1 Mutations in Canadian Breast and Ovarian Cancer Families, Nat. Genet., 1994, vol. 8, no. 4, pp. 392–398.PubMedCrossRefGoogle Scholar
  27. 27.
    Backe, J., Hofferbert, S., Skawran, B., Dork, T., Stuhrmann, M., Karstens, J.H., Untch, M., Meindl, A., Burgemeister, R., Chang-Claude, J., and Weber, B.H., Frequency of BRCA1 Mutation 5382insC in German Breast Cancer Patients, Gynecol Oncol., 1999, vol. 72, no. 3, pp. 402–406.PubMedCrossRefGoogle Scholar
  28. 28.
    Vehmanen, P., Friedman, L.S., Eerola, H., McClure, M., Ward, B., Sarantaus, L., Kainu, T., Syrjakoski, K., Pyrhonen, S., Kallioniemi, O.P., Muhonen, T., Luce, M., Frank, T.S., and Nevanlinna, H., Low Proportion of BRCA1 and BRCA2 Mutations in Finnish Breast Cancer Families: Evidence for Additional Susceptibility Genes, Hum. Genet., 1997, vol. 6, no. 13. pp. 2309–2315.Google Scholar
  29. 29.
    Johannsson, O., Ostermeyer, E.A., Hakansson, S., Friedman, L.S., Johansson, U., Sellberg, G., Brondum-Nielsen, K., Sele, V., Olsson, H., King, M.C., and Borg, A., Founding BRCA1 Mutations in Hereditary Breast and Ovarian Cancer in Southern Sweden, Amer. J. Hum. Genet., 1996, vol. 58, no. 3, pp. 441–450.PubMedGoogle Scholar
  30. 30.
    Hakansson, S., Johannsson, O., Johansson, U., Sellberg, G., Loman, N., Gerdes, A.M., Holmberg, E., Dahl, N., Pandis, N., Kristoffersson, U., Olsson, H., and Borg, A., Moderate Frequency of BRCA1 and BRCA2 Germ-Line Mutations in Scandinavian FBC, Amer. J. Hum. Genet., 1997, vol. 60, no. 5, pp. 1068–1078.PubMedGoogle Scholar
  31. 31.
    Andersen, T.I., Borresen, A.L., and Moller, P., A Common BRCA1 Mutation in Norwegian Breast and Ovarian Cancer Families?, Amer. J. Hum. Genet., 1996, vol. 59, no. 2, pp. 486–487.PubMedGoogle Scholar

Copyright information

©  2008

Authors and Affiliations

  • H. Rassi
    • 1
  • N. G. Gorovenko
    • 1
  • M. Houshmand
    • 2
  • S. V. Podolskaya
    • 1
  • M. Hashemi
    • 3
  • K. Majidzadeh
    • 5
  • M. H. Hosseini Akbari
    • 4
  • M. Shafa Shariat Panahi
    • 2
  1. 1.National Medical AcademyKyivUkraine
  2. 2.National Institute for Genetic Engineering and BiotechnologyTehranIran
  3. 3.Khatam HospitalTehranIran
  4. 4.Baghiatollah HospitalTehranIran
  5. 5.Iranian Breast Cancer CenterTehranIran

Personalised recommendations